Compare Boston Scientific Corporation (BSX) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Sibanye Stillwater Ltd — how do they compare? Boston Scientific Corporation trades at $43.29 (market cap $66.37B), while Sibanye Stillwater Ltd trades at $8.53 (market cap $6.03B). The key difference: Boston Scientific Corporation is far larger — about 11× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays a 3.63% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | SBSW | |
|---|---|---|
Market Cap | $66.37B | $6.03B |
Sector | Health | Basic Materials |
52-Week High | $108.14 | $21.12 |
52-Week Low | $42.63 | $7.27 |
Enterprise Value | $75.94B | $7.66B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Sibanye Stillwater (SBSW) trades at $8.42, down 1.52% with bearish technical signals. The company shows mixed fundamentals with a negative net income margin of -3.99% and ROE of -12.38% for 2024, though revenue has stabilized at $112.13B. Recent news highlights a turnaround narrative with EBITDA growth and debt reduction plans. Technical indicators show bearish momentum with support at $8 and resistance at $9.
The stock presents a high-risk opportunity with significant upside to the $14.25 consensus price target. Key risks include persistent negative profitability, high debt levels, and commodity price volatility. Analyst sentiment is cautiously optimistic with 43% buy ratings, but investors should weigh the turnaround potential against ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
